SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Valens takes the Green Road south

    By

    Kelowna-based The Valens Company’s US market strategy is giving us hope for Canadian cannabis after making a $40 million deal (USD) in the American CBD market.

    America’s largest CBD company

    On Tuesday, Valens announced it was acquiring Florida-based Green Roads, the largest privately-owned CBD company with 7,000 storefronts plus e-commerce services, in the cash and stock deal. Green Roads will receive an additional $20 million if they meet targets.

    “We evaluated what would strategically make the most sense as our first piece of the puzzle in our US market strategy,” CEO Tyler Robson said in a statement.



    But wait, there’s more…

    Valens has also applied to list shares on the Nasdaq, which will require shareholders to vote on consolidating shares on May 25.

    “We believe that listing in the U.S. will unlock various opportunities to enhance corporate visibility, increase liquidity and broaden overall awareness of The Valens Company to a larger investor base while driving value for our shareholders,” said president Jeff Fallows in a  press release

    Shares of Valens will continue to be listed on the Toronto Stock Exchange, where they trade as VLNS.

    10 June 2026 · Berlin Sales end May 29

    European Cannabis
    Insights Summit

    From €216

    200+ industry leaders. Exclusive German market data. A half-day briefing for B2B operators in Europe's most important emerging cannabis market.

    BofC

    Share Article

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free